Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GLP1R drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GLP1R ECD-Fc Fusion Protein & Mutant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 expressed for native glycosylation. |
View GLP1R Products |
| Gene Delivery | GLP1R Lentivirus Premade Particles Full-length ORF for stable cell line construction. Preserves native GPCR conformation for cAMP & calcium flux assays. |
View GLP1R Products |
| Benchmark Ab | Anti-GLP1R Antibody (Reference Sequence) Recombinant positive control for binding/competition assays and receptor occupancy. |
View GLP1R Products |
| Validator | GLP1R siRNA Set For knockdown verification and specificity controls. |
View GLP1R Products |
| Related Target A | GIPR (Gastric Inhibitory Polypeptide Receptor) Synergistic twincretin pathway; essential for Tirzepatide/Retatrutide mechanism studies. |
View GIPR Products |
| Related Target B | GCGR (Glucagon Receptor) Triple agonist development (GLP-1/GIP/Glucagon); metabolic expenditure regulation. |
View GCGR Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Bias Signaling Differentiation (G-protein vs β-arrestin) | Lentivirus-encoded GLP1R for stable cell lines; native conformation enables BRET/PathHunter assays for biased agonism screening. |
| Cross-species Evaluation (Cyno/Mouse/Human) | Human/Mouse/Cyno ortholog proteins available with >95% purity; full-length lentivirus for transgenic cell lines. Sequence verified by mass spec. |
| Off-target Specificity (GLP2R, Calcitonin R, etc.) | Strict homology panel proteins (GLP2R, GIPR, GCGR) for counter-screening; >95% purity eliminates false binding. |
| Lack of Reference Controls | Clinical benchmark detection antibodies and reference peptide agonists included. |
| False Positives in Cell Assays | Validated siRNA included for receptor-specificity checks and endogenous knockdown. |
| High-concentration Formulation Stability | ECD-Fc fusion validated for stability at >10 mg/mL; suitable for subcutaneous delivery modeling. |
Live GLP1R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GLP1R therapeutics is intensifying, with major players shifting focus from traditional peptide injections to oral small molecules and multi-receptor agonists. As first-generation therapies (semaglutide, tirzepatide) dominate the T2D and obesity markets, the next wave of R&D is targeting NASH, cardiovascular risk reduction, and neurodegenerative diseases such as Alzheimer's. Key trends include biased signaling to improve tolerability, muscle-sparing combination therapies (e.g., with myostatin inhibitors), and once-daily oral dosing. The convergence of GLP1R with GIPR and GCGR in single molecules is redefining efficacy benchmarks, creating acute demand for selectivity assays and species-crossover validation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Agonist (Injectable) | Novo Nordisk, Eli Lilly | T2D, Obesity, NASH | Receptor internalization & cAMP flux; need full-length Lentivirus cell lines for accurate membrane expression. |
| Oral Small Molecule | Eli Lilly, Pfizer, Novo Nordisk, Roche | T2D, Obesity | Allosteric screening; need pure ECD-Fc and mutant proteins for binding and selectivity assays. |
| Multi-receptor Agonist (Dual/Tri) | Eli Lilly (Retatrutide), Viking Therapeutics, Boehringer Ingelheim | Severe Obesity, NASH, MASH | Heterodimer validation and selectivity; need cross-reactive GLP1R/GIPR/GCGR panels. |
| Antibody/Fusion Protein | Amgen (AMG 133) | Metabolic Disorders | Half-life and affinity optimization; need high-purity ECD-Fc for SPR/BLI. |
| Gene/Cell Therapy | Academic/Preclinical | Rare metabolic disorders | Stable GLP1R expression; need high-titer Lentivirus for cell line construction. |
Key Genetic Variants
Functional polymorphisms in GLP1R are associated with metabolic traits and drug response. Key mutations include:
- rs10305420 (UniProt P43220 VAR_018924)
- rs10305421 (UniProt P43220 VAR_018925)
- rs2295006 (UniProt P43220 VAR_018926)
These variants may affect receptor activity, signaling bias, or clinical outcomes, highlighting the need for mutant-specific assay reagents available through TarMart.